Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
A phase 1/2 trial of Photodynamic Therapy (PDT) in prostate cancer, run by SpectraCure AB, now recruiting.
Overview
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT06807359 by SpectraCure AB, with 43 participants planned, started 2025-01-06 and due to reach its primary completion in 2028-01. Interventions recorded: Photodynamic Therapy (PDT) and Verteporfin Injection.
Similar pages
not linked directly; found by shared links- TrialClinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Shares SpectraCure, Prostate cancer and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.